JP2013184887A5 - - Google Patents

Download PDF

Info

Publication number
JP2013184887A5
JP2013184887A5 JP2012048422A JP2012048422A JP2013184887A5 JP 2013184887 A5 JP2013184887 A5 JP 2013184887A5 JP 2012048422 A JP2012048422 A JP 2012048422A JP 2012048422 A JP2012048422 A JP 2012048422A JP 2013184887 A5 JP2013184887 A5 JP 2013184887A5
Authority
JP
Japan
Prior art keywords
sap155
inhibitor
firδexon2
fir
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012048422A
Other languages
English (en)
Japanese (ja)
Other versions
JP6057408B2 (ja
JP2013184887A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012048422A priority Critical patent/JP6057408B2/ja
Priority claimed from JP2012048422A external-priority patent/JP6057408B2/ja
Publication of JP2013184887A publication Critical patent/JP2013184887A/ja
Publication of JP2013184887A5 publication Critical patent/JP2013184887A5/ja
Application granted granted Critical
Publication of JP6057408B2 publication Critical patent/JP6057408B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012048422A 2012-03-05 2012-03-05 癌の予防剤および/または治療剤 Active JP6057408B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012048422A JP6057408B2 (ja) 2012-03-05 2012-03-05 癌の予防剤および/または治療剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012048422A JP6057408B2 (ja) 2012-03-05 2012-03-05 癌の予防剤および/または治療剤

Publications (3)

Publication Number Publication Date
JP2013184887A JP2013184887A (ja) 2013-09-19
JP2013184887A5 true JP2013184887A5 (enExample) 2015-04-23
JP6057408B2 JP6057408B2 (ja) 2017-01-11

Family

ID=49386650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012048422A Active JP6057408B2 (ja) 2012-03-05 2012-03-05 癌の予防剤および/または治療剤

Country Status (1)

Country Link
JP (1) JP6057408B2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6304594B2 (ja) * 2014-05-29 2018-04-04 国立大学法人千葉大学 芳香環含有化合物並びに癌の予防剤および/または治療剤
ES2887201T3 (es) 2015-09-01 2021-12-22 Eisai R&D Man Co Ltd Variantes de empalme asociadas con mutantes neomórficos de SF3B1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2510087A2 (en) * 2009-12-11 2012-10-17 The Brigham and Women's Hospital, Inc. Pathogen restriction factors
WO2011129427A1 (ja) * 2010-04-16 2011-10-20 第一三共株式会社 癌の診断剤および治療剤

Similar Documents

Publication Publication Date Title
JP2011168588A5 (enExample)
GB201317477D0 (en) Methods, compositions and kits for determing the presence/absnece of a variant nucleic acid sequence
MX367666B (es) Composiciones y métodos para cuantificar una secuencia de ácido nucleico en una muestra.
IN2014DN04226A (enExample)
JP2017522908A5 (enExample)
PL4397760T3 (pl) Kompozycja do rozszczepiania docelowego dna zawierająca prowadzące rna specyficzne dla docelowego dna i kwas nukleinowy kodujący białko cas lub białko cas oraz jej zastosowanie
WO2008151631A8 (en) Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
CL2011002524A1 (es) Compuestos derivados de 1,3-diazol-fenil-(etinil, etenil o ciclopropil)-fenil-1,3-diazol sustituidos, inhibidores ns5a; composicion farmaceutica que los comprende y su uso en tratamiento de la hepatitis c.
UA118649C2 (uk) ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR)
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
WO2008113111A8 (en) Assay for gene expression
EP2379561A4 (en) MLK INHIBITORS AND METHOD OF USE
WO2012149339A3 (en) Quantification of a minority nucleic acid species
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201490993A1 (ru) МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи
TR201815882T4 (tr) Tal efektörü aracılı dna modifikasyonu.
EP2271329A4 (en) METHOD, COMPOSITIONS AND SETS FOR TREATING PAIN AND PRURITIS
ATE461699T1 (de) Verbesserte biologische wirkungen von zusammensetzungen, die rosmarinsäure enthalten
CL2008001517A1 (es) Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga.
EA201290822A1 (ru) Триазолоны в качестве ингибиторов синтазы жирных кислот
BR112014029274A2 (pt) anticorpo isolado, composição farmacêutica, uso do anticorpo, método para tratar infecção rábica, kit para tratar infecção rábica, kit para detectar vírus rábico, ácido nucleico isolado, e, célula hospedeira.
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
WO2011153234A3 (en) Methods of inhibiting alu rna and therapeutic uses thereof
ATE505562T1 (de) Doppel-oligonukleotid- nukleinsäurenachweisverfahren
WO2012021493A3 (en) Compositions and methods for quantifying a nucleic acid sequence in a sample